Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125

Abstract

Although the uncontrolled design of this study prevents definitive conclusions with respect to subgroups, the data support a relationship between Ab3 response and survival time. Thus, the need for further randomized, controlled clinical trials to establish efficacy of the vaccine ACA125 seems to be indicated.